News
GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...
Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation ...
British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...
GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...
GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...
CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...
Second-quarter sales rose to £7.99 billion from £7.88 billion in the same period the year prior.
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...
GSK ( NYSE: GSK) CEO Emma Walmsley said on Wednesday that her company is in discussions with the Trump administration on how ...
British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...
The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback